January 12, 2017
Ablynx starts Phase IIb RESPIRE study of RSV infections treatment
Ablynx has dosed the first patient in the Phase IIb “RESPIRE” dose-ranging efficacy study of ALX-0171, its novel inhaled drug…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
January 12, 2017
Celyad: First pancreatic cancer patient in its CAR-T NKR-2THINK trial in Belgium
Celyad has activated a second clinical site in Belgium for the , with the registration of a pancreatic cancer patient…
January 11, 2017
ValiRx encouraged by initial trials of cancer drug study, expands to more sites
A clinical stage biotechnology company, ValiRX, said on Wednesday that its VAL201 personalised Phase l/II prostate cancer study brought positive results.
January 11, 2017
Premaitha closes deal on Yourgene acquisition
Premaitha Health’s shareholders have approved the acquisition of Yourgene, a bioinformatics specialist based in Taiwan. The purchase was approved on Tuesday afternoon.
January 11, 2017
Director Jonathan Freeman’s Dealings
Futura Medical, the innovative healthcare company focused on advanced transdermal technology has been notified that on 10 January 2017, Jonathan…
January 11, 2017
Genfit: half-year report of liquidity contract with CIC
GENFIT, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that affect the liver…
January 10, 2017
Sareum Holdings monetizes on partnership deal with Sierra Oncology and other partners
Sareum Holdings, a drugmaker focused on cancer drugs on Monday announced cashing a $2.0 million milestone payment as part of the Chk1 licence agreement between its co-investment partner, the CRT Pioneer Fund, and Sierra Oncology, formerly known as ProNAi Therapeutics.
January 10, 2017
NeuroVive,Karolinska Institutet collaboration on mitochondrial myopathy treatment
NeuroVive Pharmaceutical AB, the mitochondrial medicine company, has signed collaboration agreement with Karolinska Institutet, Stockholm, Sweden, regarding development of the company’s…
January 10, 2017
Abivax cashes €8.4 million from Bpifrance for antiviral drugs research
Abivax said on Tuesday it would receive €8.4 million from “Projets de R&D Structurants Pour la Compétitivité” (PSPC) of the “Invest in the Future Program” (PIA).
January 10, 2017
Novo Nordisk’s diabetes drug available in Europe in the first half of 2017
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.